Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 1/20 | 0.58 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.52 |
| ▸ | TSPO | P30536 | 3/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3027889 | 0.87 | PSMD14 (0.59) | PSMD14GABRA2GABRB2TSPONR1I2 | |
| SCHEMBL3022537 | 0.84 | GABRA2 (0.66) | PSMD14GABRA2GABRB2TSPONR1I2 | |
| SCHEMBL7261 | 0.81 | GABRA2 (0.68) | GABRA2GABRB2TSPONR1I2ABCB11 | |
| SCHEMBL3021592 | 0.79 | ALDH1A1 (0.70) | PSMD14GABRA2GABRB2TSPONR1I2 | |
| SCHEMBL3026882 | 0.78 | PSMD14 (0.48) | PSMD14GABRA2GABRB2 | |
| SCHEMBL3035121 | 0.76 | TSPO (0.71) | PSMD14GABRA2GABRB2TSPONR1I2 | |
| SCHEMBL15331333 | 0.73 | PSMD14 (0.53) | PSMD14GABRA2GABRB2 | |
| SCHEMBL1430336 | 0.71 | GABRA2 (0.63) | GABRA2GABRB2TSPONR1I2ABCB11 | |
| SCHEMBL14302332 | 0.71 | TSPO (0.53) | GABRA2GABRB2TSPONR1I2ABCB11 | |
| SCHEMBL8150 | 0.70 | GABRA2 (0.70) | GABRA2GABRB2TSPONR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2752415-B1 | Fluorinated ligands for targeting peripheral benzodiazepine receptors | AUSTRALIAN NUCLEAR SCIENCE & TECH ORGANISATION (AU) | 2017-10-11 | — | — | EP | disclosed |
| EP-2752415-A1 | Fluorinated ligands for targeting peripheral benzodiazepine receptors | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) | 2014-07-09 | — | — | EP | disclosed |
| US-20100209345-A1 | Fluorinated Ligands for Targeting Peripheral Benzodiazepine Receptors | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION | 2010-08-19 | — | — | US | disclosed |
| EP-2054060-A1 | FLUORINATED LIGANDS FOR TARGETING PERIPHERAL BENZODIAZEPINE RECEPTORS | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008022396-A1 | FLUORINATED LIGANDS FOR TARGETING PERIPHERAL BENZODIAZEPINE RECEPTORS | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209345-A1 | Fluorinated Ligands for Targeting Peripheral Benzodiazepine Receptors | GABRA6, GABRA1, GABRA2 | PSMD14 4214/4885GABRA2 3/4885GABRB2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.